Keywords: numax, reduces, rsv, ph, trial, maryland, usa-based

Numax reduces RSV in Ph 1 trial

Article | 12 September 2005

Print This

Maryland, USA-based group MedImmune has released data from Phase I trials of its antiviral compound Numax (motavizumab). The results suggest ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in